Pfizer, AstraZeneca Effective Against Virus Strain Found in India

The Pfizer-BioNTech and Oxford-AstraZeneca vaccines have been found to be highly effective against the coronavirus variant that was first identified in India, according to a study by Public Health England (PHE).

The Pfizer vaccine was 88-percent effective and the AstraZeneca jab was 60-percent effective against the B1617.2 strain after the second dose.

Both the vaccines were more effective against the so-called “Kent” strain – B.1.1.7, the COVID-19 variant dominant in Britain – with Pfizer being 93-percent effective while the AstraZeneca jab was 66-percent effective over the same period.

However, they were only 33-percent effective three weeks after the first dose.

Health Secretary Matt Hancock described the outcome as “groundbreaking,” while PHE said it expects to see even higher levels of effectiveness against hospital admission and death.

“This new evidence is groundbreaking and proves just how valuable our COVID-19 vaccination programme is in protecting the people we love,” Hancock said.

Earlier this month, the World Health Organization (WHO) dubbed the B1617.2 strain a “variant of global concern”.

The study, which took place between April 5 and May 16, found that both the vaccines were 33-percent effective against symptomatic disease from the B1617.2 strain three weeks after the first dose, compared with about 50 percent against the B.1.1.7 strain.

Some 12,675 genome-sequenced cases were included in the analysis, but only 1,054 were of the variant identified in India. The study included data for all age groups from April 5 to cover the period since the strain emerged.

Separate analysis by PHE indicates that the vaccination programme has so far prevented 13,000 deaths and about 39,100 hospital admissions in older people in England, up to May 9.

Under the government’s plans, a lifting of remaining coronavirus restrictions is due to take place from June 21.

The latest figures show that more than 50 million doses of coronavirus vaccine have been given in Britain in Europe’s fastest vaccination programme so far, but it has faced a new challenge from the spread of the variant first found in India.

Data published on Saturday showed new COVID cases reported in Britain rose by 10.5 percent in the seven days to May 22 although it remained a fraction of levels seen earlier this year.

Follow us on: